Morning Briefing
Summaries of health policy coverage from major news organizations
Small Phase I Trial Shows HIV Vaccine Candidate Is Most Powerful To Date
Researchers at the Spanish Superior Scientific Research Council (CSIC) have successfully completed a small Phase I human clinical trial of an HIV vaccine candidate that granted 90 percent of 30 study participants an immunological response against the virus, Gizmag reports. "The MVA-B vaccine draws on the natural capabilities of the human immune system and 'has proven to be as powerful as any other vaccine currently being studied, or even more,' says Mariano Esteban, head researcher from CSIC's National Biotech Centre," the magazine writes (Borgobello, 9/28).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
